Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention (NCT07156591) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention
China460 participantsStarted 2025-09-15
Plain-language summary
A prospective, single-center, observational study to compare the risk of gastric retention between the exposure group (with neuropathy) and non-exposure group (without neuropathy) in diabetic patients receiving uninterrupted semaglutide therapy
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Confirmed diagnosis of diabetes mellitus.
* Long-term use of semaglutide (for at least 4 weeks) without discontinuation prior to endoscopic examination.
* Age ≥ 18 years, with no restriction on sex.
* American Society of Anesthesiologists (ASA) physical status classification I-II.
* Fasting for at least 8 hours and no water intake for at least 4 hours prior to gastroscopy.
* Underwent assessment for both autonomic and peripheral neuropathy within 2 weeks prior to gastroscopy, with a clear determination of neuropathy status.
Exclusion Criteria:
* History of hiatal hernia or any prior gastric surgery (including gastrectomy, Roux-en-Y gastric bypass, etc.).
* Pregnancy.
* Medically unfit for gastrointestinal endoscopy.
* Deemed unsuitable for participation at the discretion of the investigators.
What they're measuring
1
Rate of gastric retention
Timeframe: immediately after the esophagogastroduodenoscopy